[
    [
        {
            "time": "",
            "original_text": "华大基因：部分产品及服务涉嫌侵犯专利，控股子公司及关联公司在香港被起诉 关联方问题",
            "features": {
                "keywords": [
                    "华大基因",
                    "专利侵权",
                    "控股子公司",
                    "关联公司",
                    "香港诉讼"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华大基因：部分产品及服务涉嫌侵犯专利，控股子公司及关联公司在香港被起诉 关联方问题",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "华大基因：相关诉讼对于新冠检测服务与新冠检测试剂盒的销售不构成重大不利影响 诉讼纠纷",
            "features": {
                "keywords": [
                    "华大基因",
                    "新冠检测",
                    "试剂盒",
                    "诉讼",
                    "销售影响"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗健康",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因：相关诉讼对于新冠检测服务与新冠检测试剂盒的销售不构成重大不利影响 诉讼纠纷",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "华大基因：相关诉讼对于新冠检测服务与新冠检测试剂盒的销售不构成重大不利影响",
            "features": {
                "keywords": [
                    "华大基因",
                    "新冠检测",
                    "试剂盒",
                    "诉讼",
                    "销售影响"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗健康",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华大基因：相关诉讼对于新冠检测服务与新冠检测试剂盒的销售不构成重大不利影响",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "中国生物科技服务(8037.HK)大涨超14%与华大基因合资设新型肺炎检测实验室",
            "features": {
                "keywords": [
                    "中国生物科技服务",
                    "华大基因",
                    "新型肺炎检测",
                    "合资实验室",
                    "股价上涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技",
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国生物科技服务(8037.HK)大涨超14%与华大基因合资设新型肺炎检测实验室",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "中国生物科技服务(08037-HK)伙华大基因设新型肺炎检测实验室",
            "features": {
                "keywords": [
                    "中国生物科技服务",
                    "华大基因",
                    "新型肺炎检测",
                    "合作实验室"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技",
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国生物科技服务(08037-HK)伙华大基因设新型肺炎检测实验室",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]